 |
 |

Enhanced Effectiveness of Intraperitoneal Antibiotics Administered via Liposomal Carrier
Carl I. Price, MD;
Jureta W. Horton, PhD;
Charles R. Baxter, MD
Arch Surg. 1989;124(12):1411-1415.
Abstract
 |  |
The local application of antibiotics to treat intraperitoneal contamination has been used with variable results. Liposomes are not rapidly absorbed from the peritoneal cavity, offering a potential delivery system for intraperitoneal antibiotics. The effects of liposome-incorporated antibiotic administration in a fecal peritonitis model were compared with the effects of conventional intraperitoneal and intramuscular antibiotics. Rats were divided into four groups: untreated, intramuscular cefoxitin, intraperitoneal cefoxitin, and intraperitoneal liposome-incorporated cefoxitin. Quantitative blood cultures were drawn at 4 and 24 hours. Liposome delivery of cefoxitin significantly reduced mortality and bacteremia at 4 and 24 hours compared with control subjects and conventional antibiotic groups. Peritoneal abscess formation tended to decrease in the liposome antibiotic group (mean ± SEM, 6.86 ± 0.79) compared with the group receiving free intraperitoneal administration of antibiotics (10.33± 1.63). We conclude that liposomal delivery significantly enhances the effectiveness of cefoxitin in this model of peritonitis.
(Arch Surg. 1989;124:1411-1415)
Author Affiliations
From the Departments of Surgery, the University of Texas Southwestern Medical Center, Dallas (Drs Horton and Baxter) and the University of Oklahoma Health Science Center, Oklahoma City (Dr Price).
Footnotes
Accepted for publication August 7, 1989.
Read before the Ninth Annual Meeting of the Surgical Infection Society, Denver, Colo, April 13, 1989.
Reprint requests to the Department of Surgery, the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75235-9031 (Dr Horton).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies
Schiffelers et al.
J Antimicrob Chemother 2001;48:333-344.
ABSTRACT
| FULL TEXT
|